AbbVie director Jennifer L. Davis resigns effective Nov. 2, 2026
ABBV•AbbVie Class II director Jennifer L. Davis will resign from the board effective November 2, 2026, citing her recent appointment as CEO of Align Technology. She said the resignation is not due to any dispute or disagreement with AbbVie.
1. Board resignation
Jennifer L. Davis notified AbbVie's board on October 28 that she would resign as a Class II director effective November 2, 2026. She cited her recent appointment as CEO of Align Technology and said her resignation does not stem from a dispute or disagreement over AbbVie's operations, policies or practices.
